Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodSingle-cell Genomics in AML: Extending the Frontiers of AML Research

Researchers studying acute myeloid leukemia (AML) have been able to better characterize the disease, improve risk-stratification methods, and create new treatments thanks to the era of genomic medicine. Despite major advancements, AML’s extremely intricate and plastic cellular architecture means that it is still a fatal malignancy. Because it makes it difficult to pinpoint and then eliminate the cells that cause leukemogenesis and therapy failure, this level of heterogeneity continues to be a significant obstacle. Single-cell genomics has made unheard-of advancements in the study of cellular heterogeneity in recent years, and it shows promise for the investigation of AML.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form